Johann Ohly, MD
Ophthalmology · Overland Park, KSNPI 1336348820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Alcon at 26.4% of the total.
Across 172 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$582
- Johnson & Johnson Surgical Vision, Inc.$342
- Carl Zeiss Meditec USA, Inc.$241
- Bausch & Lomb Americas Inc.$231
- Bausch & Lomb, A Division Of Bausch Health US, LLC$220
- plus $1K from 23 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$500
What the payments were for
- Food & beverage$4,05697%
- Education$1133%
- Other$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 51 | $1,109 |
| AbbVie(2 entities) | 19 | $582 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $342 |
| Carl Zeiss Meditec USA, Inc. | 3 | $241 |
| Bausch & Lomb Americas Inc. | 11 | $231 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $220 |
| Oyster Point Pharma, Inc. | 8 | $138 |
| Rxsight Inc | 8 | $135 |
| Coopervision Inc. | 3 | $126 |
| Dompe US, Inc. | 5 | $116 |
| Sun Pharmaceutical Industries Inc. | 5 | $115 |
| Tarsus Pharmaceuticals, Inc. | 4 | $111 |
| Kala Pharmaceuticals, Inc. | 5 | $98 |
| Biotissue Holdings Inc. | 3 | $84 |
| Thea Pharma Inc. | 3 | $73 |
| Aerie Pharmaceuticals, Inc. | 3 | $66 |
| The Cameron-ehlen Group, Inc. | 3 | $57 |
| Harrow Eye, LLC | 3 | $52 |
| Amgen | 3 | $47 |
| Sight Sciences, Inc. | 3 | $45 |
| Ivantis, Inc | 3 | $44 |
| Glaukos Corporation | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Lumenis, Inc | 1 | $22 |
| Spark Therapeutics, Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Kerecis Limited | 1 | $16 |
| Lombart Brothers, Inc. | 1 | $13 |
| Ocular Therapeutix, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ophthalmic Surgical Adjuncts$375
- Centurion$274
- Clareon$267
- LUMERA 700$164
- Clareon PanOptix Pro$149
- DURYSTA$120
- XEN GLAUCOMA TREATMENT SYSTEM$115
- XEN$111
How this compares
$4,199 in reported general payments places this provider in the 80th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 156 | $60,435 |
| RestasisCyclosporine | 29 | $27,708 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 89 | $18,166 |
| Latanoprost | 1,833 | $17,765 |
| Cyclosporine | 12 | $12,796 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $12,246 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $10,582 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 554 | $9,405 |
| Travoprost | 66 | $7,826 |
| VyzultaLatanoprostene Bunod | 20 | $7,612 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 28 | $6,930 |
| Cosopt PfDorzolamide/Timolol/Pf | 16 | $4,646 |
| Prednisolone Acetate | 119 | $3,980 |
| Brimonidine Tartrate | 250 | $3,580 |
| Brinzolamide | 13 | $2,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $582 | $98,725229 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $66 | $12,24622 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $231 | $7,61220 claims |
| AlconSimbrinza | $1,109 | $6,93028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Overland Park
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Jason StahlOverland Park$10K
- Christopher KetchersideOverland Park$6K
- Selena FuOverland Park$5K
- Timothy CavanaughOverland Park$5K
- Keith WarrenOverland Park$4K
- Austin AndersenOverland Park$3K
- Kristin Schmid BiggerstaffOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.